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Abstract
Biomarkers are biological indicators of processes that are part of ethiopathogenesis of the 
diseases, and can, but do not have to be causal to diseases. One very important question 
is how specific and sensitive the marker is, since one molecule can appear in many con-
ditions. Biomarkers of endothelial cell activation can be very diverse, from biochemical/
metabolic to functional biomarkers. Activation of endothelial cells is part of physiological 
as well as pathophysiological response of cardiovascular system in conditions as physical 
activity, growth, pregnancy and in all cardiometabolic diseases (e.g., hypertension, dia-
betes mellitus, autoimmune inflammatory diseases, coronary artery disease, atheroscle-
rosis, ischemia and reperfusion, etc.). During activation, there is a change in endothelial 
cell morphology and function, which could be a defensive response of endothelium to 
provoking factor or could lead to increased risk for the injury and end organ damage. 
This chapter aims to overview current knowledge on established biomarkers of normal 
and disease-related endothelial activation and to provide information on novel, potential 
biomarkers in common cardiometabolic diseases.
Keywords: endothelial activation, biomarkers, laser Doppler flowmetry, flow mediated 
dilation, pregnancy, exercise, cardiometabolic diseases, functional markers, nitric oxide, 
prostaglandins
1. Introduction
Vascular endothelium has a critical role in maintaining vascular tone, and changes in vascular 
flow are in complex interactions with endothelium. The importance of this particular function 
of the endothelium manifests in the fact that the term “endothelial function” is usually used to 
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describe the ability of endothelium to release vasoactive substances and thereby regulate blood 
flow. The basic principle of vascular function is that healthy blood vessels dilate normally and the 
diseased blood vessels exhibit a dysfunctional vasodilation. Therefore, all methods for endothelial 
function assessment are based on the ability of endothelium to respond (vasodilation or vasocon-
striction) to a specific stimulus (vascular occlusion, pharmacological vasodilators, heating, etc.).
Biomarkers are biological indicators of processes that are part of etiology of the diseases, and 
can, but do not have to be causal to diseases. One very important question is how specific 
and sensitive the marker is, since one molecule can appear in many conditions. Biomarkers 
of endothelial cell activation can be very diverse: biochemical/metabolic (such as plasma 
glucose, lipids, cytokines, asymmetric dimethylarginine (ADMA), high sensitive C-reactive 
protein (hsCRP), myeloperoxidase (MPO), cell adhesion molecules (CAMs), markers of 
coagulability, markers of oxidative stress, chemokines, microparticles, endothelial progenitor 
cells), functional biomarkers (such as flow-mediated dilation and other types of flowmetry, 
arteriographic measurements of vascular function) and structure (e.g., CIMT—carotid intima-
media thickness, angiogenesis, or rarefaction).
2. Biochemical biomarkers of vascular (endothelial) function
Over the last three decades, a number of methodological approaches were developed in order 
to evaluate and measure (patho)physiological function of the endothelium in humans [1, 2]. 
Evidently, these new methods intensified research and brought novelties in the field of vas-
cular physiology and pathophysiology, but still are not implemented as clinical tools in daily 
practice. The approaches for endothelial function assessment were designed to provide insight 
into vascular/endothelial function in different sites (vascular beds) and different blood ves-
sel types (conductive, resistant, and microcirculation). Earlier methods were more invasive 
(e.g., intracoronary infusion of acetylcholine (ACh), and later developed techniques that were 
less invasive have focused on peripheral circulation (forearm circulation) as a surrogate for 
coronary arteries [3–5]. As expected, all of these methods have their advantages and accepted 
limitations, and neither of the developed methods does present the absolute standard for the 
evaluation of endothelial function, in both macro- and microcirculation.
There is an extensive body of evidence reporting that generalized endothelial dysfunction 
exhibited virtually in every arterial bed presents an early manifestation of a variety of car-
diovascular diseases (CVDs) [6, 7]. Still, when investigating endothelial function in different 
CVDs, diverse (patho)physiological role of large conductance vessels and small microvascu-
lature should be considered.
There are many various molecules which have been denoted as vascular or endothelial mark-
ers, e.g., lipids, cytokines, ADMA, hsCRP, MPO, CAMs, markers of coagulability, markers 
of oxidative stress, chemokines, microparticles, and endothelial progenitor cells. It has been 
demonstrated that reduced bioavailability of nitric oxide (NO) plays a central role in impaired 
vascular/endothelial response (endothelial dysfunction) in conduit arteries, while NO in the 
microcirculation primarily modulates tissue metabolism [8]. On the other hand, a number of 
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studies indicate that endothelium-derived hyperpolarizing factor (EDHF) plays a major role 
in vasodilation in skin microcirculation [9], whereas the results are still conflicting concerning 
the implication of prostaglandins [10–12]. A study on coronary endothelial function in young 
smokers reported that they had epicardial coronary endothelial dysfunction but preserved 
microvascular endothelial function [13].
2.1. Biomarkers in pregnancy
The importance of maternal vascular adaptation to pregnancy is to increase blood flow and to 
assure the proper development of the fetus. Several possible biochemical biomarkers have been 
proposed to evaluate vascular/endothelial function in pregnancy. First among them is NO, one 
of most important endothelial vasodilators, which is produced by NO synthase (NOS). It is 
well accepted that NOS-3 expression levels are increased in uterine artery endothelium in preg-
nancy [14]. Prostacyclin (PGI2) also plays an important role in vasodilator response, and its con-
centration is elevated in pregnancy [15]. In order to estimate the real impact of prostacyclin on 
vascular tone, determination of thromboxane a2 (TXA2)/PGI2 ratio is needed. Since both TXA2 
and PGI2 have very short half-life, only indirect measures can be made of stable metabolites in 
the blood (thromboxane b2 (TXB2) and 6-keto-prostaglandin F2a (6-ketoPGF2A)), and there is 
no technique which allows their monitoring in real time. It has been demonstrated that cycloox-
ygenase 1 (COX1) is upregulated in endothelial cells during pregnancy, and therefore induces 
a PGI2 increment [14]. EDHF is the third major player in endothelial vasodilation in pregnancy, 
causing smooth muscle relaxation. As it is not a single factor and there is still ongoing research 
to identify its specific components, it is described as spectrum of responses that are neither NO 
nor PGI2 mediated. Another limiting problem is that there is no appropriate method for its 
tracking. Although EDHF may seem as unnecessary pathway beside NO and PGI2, a number 
of studies showed an important role of EDHF in endothelium vasodilation in pregnancy, sug-
gesting that without EDHF, there would not be sufficient blood flow to the fetus [16].
Endogenous eNOS inhibitor ADMA concentrations were found to be significantly lower in 
pregnant women. However, this did not explain the improved flow-mediated dilation (FMD) 
in the correlation analysis [17, 18]. Also, endothelial function in normal pregnancy was not 
attenuated despite the significant increase in hsCRP, and pregnancy-related changes in the 
concentrations of proinflammatory cytokines, e.g., tumor necrosis factor alpha (TNF-α) and 
interleukin 6 (IL-6), were nonsignificant [19].
2.2. Biomarkers in exercise
It has been reported that the regulation of the NO-dependent pathway presents a key mecha-
nism mediating endothelial adaptations to shear stress, including increased NO synthesis, 
increased expression and activity of antioxidative enzymes (e.g., superoxide dismutase (SOD) 
and catalase), and decreased oxidative stress level (reactive oxygen species (ROS) produc-
tion) which all increases NO bioavailability. However, recent studies demonstrated that 
COX-dependent pathway and increased PGI2 synthesis take part in endothelial adaptations 
to shear stress, as well. Furthermore, a growing body of evidence suggest that increased 
shear stress generated by increased blood flow during exercise, presents a prime signal for 
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decreased level of vasoconstrictor endothelin 1 (ET1), and inflammatory markers such as vas-
cular cell adhesion molecule 1 (VCAM-1) and monocyte chemotactic protein 1 (MCP-1) level 
[20]. Furthermore, increased endothelial NOS (eNOS) gene expression has been proposed to 
be a marker of anterograde shear stress-induced endothelial activation (result of repeated 
episodic increase in blood flow during exercise), and to have anti-atherogenic effect in endo-
thelial cell cultures [21, 22].
On the other hand, rhythmic stretching (cyclic strain) provoked by systolic blood pressure 
changes during exercise affects endothelial cell growth and NO- and EDHF-dependent vaso-
dilation pathway, and its effect depends on the blood pressure increment during exercise (e.g., 
>135 mmHg elicits inhibition of endothelial cell growth) [23]. Surprisingly, further studies on 
endothelial cell cultures have reported that rhythmic stretching can induce ROS production 
and increase the expression of cell adhesion molecules. On the other hand, ROS produced 
by cyclic strain may indirectly increase expression of eNOS [24]. It became evident that the 
time of exposure to high blood pressure/cyclic strain (continuous or pulsatile) is crucial for 
its final effect on endothelial function. Brief increases in blood pressure and ROS production 
associated with bouts of exercise may signal an increase in eNOS production and other ben-
eficial effects resulting in improved endothelial function. Chronic increases in cyclic strain 
(e.g., hypertension) may elevate ROS chronically and finally provoke development of endo-
thelial dysfunction. Thus, beside abovementioned endothelial biomarkers of inflammation 
and endothelial dysfunction, measurement of oxidative stress level and antioxidant capacity 
present suitable and commonly used markers of endothelial response to different exercise 
modes and patterns (shear stress) in both health and disease.
2.3. Biomarkers in cardiometabolic diseases
Oxidation of low density lipoproteins (oxLDL) and NO synthesis contribute to endothelial 
dysfunction, vascular aging, and disease. OxLDL and NO exert contradictory actions within 
the vascular endothelium such as: leukocyte adhesion, platelet aggregation, and vascular 
smooth muscle cell proliferation and migration [25, 26]. While oxLDL—an oxidative stress 
biomarker—has been identified as a pro-atherogenic risk factor for coronary artery disease 
(CAD), NO is a free radical signal-transducing molecule that maintains vasodilation, modu-
lates in vitro lipid peroxidation reactions and alters pro-inflammatrory gene expression. Both 
are part of complex atherosclerotic process, from initiation to plaque destabilization and coro-
nary artery disease [25, 26].
As already mentioned, ADMA is an endogenous inhibitor of NO synthase [27] and thus 
may cause endothelial dysfunction [28]. Increased plasma levels of ADMA are related with 
hyperlipidemia, hypertension, coronary artery disease, unstable angina, stroke and end-stage 
renal disease and diabetes [28]. Reduced plasma levels of ADMA after percutaneous coro-
nary intervention could be indicative of a reduced risk of recurrent cardiovascular events. 
Although ADMA was significantly associated with all-cause mortality in patients with acute 
coronary syndrome and ischemic heart disease, there is no clear association between ADMA 
and cardiovascular disease incidence [29]. Type II diabetes has been associated with increased 
ADMA levels. ADMA and NO have been found to be significant determinants of insulin resis-
tance [30]. A study performed in type 2 diabetes patients that used antidiabetic metformin for 
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3 months showed reduced serum ADMA levels for 30% [31]. Another study, from Stuhlinger 
et al. found that rosiglitazone reduced the level of ADMA by 30% in seven insulin-resistant 
non-diabetic hypertensive individuals [32].
Toll-like receptors (TLRs), such as toll-like receptors TLR2 and TLR4 have been found to have 
elevated expression in T2DM patients, which could be a possible underlying mechanism 
of inflammation in T2DM [33]. TLR-2 and TLR-4 activation has also been found in murine 
models of atherosclerosis [33, 34]. There are many unanswered questions: the consequences 
of activation/blockade of TLRs in atherosclerosis, relationship between innate and adaptive 
responses in atherosclerosis, and mechanistic insight on the intricate balance of direct and risk 
factor-mediated effects of TLRs in CVD [33, 34].
The over expression of TNF-alpha and its inflammatory and immunomodulatory effects have 
been implicated in the pathogenesis of CAD and myocardial dysfunction. Cardiovascular 
complications may be influenced by TNF-alpha gene polymorphisms. Certain studies failed 
to find a significant association between the TNF-alpha gene polymorphisms and CVD [35]. 
Further studies are required to resolve this controversy.
IL-6 is associated with the process of inflammation and coronary artery disease. Patients with 
high levels of IL-6 show worse in-hospital outcome following treatment in case of unstable 
angina. An association has been shown between the IL-6 promoter polymorphism −174G/C 
and hypertension, left ventricular hypertrophy and ischemic heart disease CAD [35].
Endothelial cells also express chemotactic factors: MCP-1, proinflammatory cytokines (macro-
phage colony-stimulating factor) and tumor necrosis factor-beta (TNF-β) [36]. Hyperglycemia 
promotes MCP-1 expression in vascular endothelial cells and has a pivotal role in the patho-
genesis of diabetic vasculopathy [37]. Patients with diabetes mellitus or obesity have increased 
circulating levels of inflammatory markers, including C reactive protein (CRP), TNF-α, and 
IL-6 [38–40]. Blood level of CRP, as independent predictor of diabetes, is increased in both 
Type I and Type II diabetes [41, 42]. TNF-α can induce cytokines such as IL-6 which regulates 
the expression of CRP. They can impair endothelial function and contribute to atherothrom-
bosis especially in patients with Type II diabetes, alone or in combination [43]. It was also 
found in male diabetic patients that increased levels of inflammatory markers predict cardio-
vascular risk in diabetic patients [44].
Microparticles, the membrane vesicles released by various cell types and circulating endo-
thelial cells represent novel biomarkers of endothelial injury, associated with atherosclero-
sis and related complications (thrombosis, inflammation, and apoptosis). Microparticles are 
suggested to be biomarkers of vascular injury and inflammation [45]. Changes in circulating 
levels of microparticles might give an important clinical information in healthy subjects or 
patients with CVDs as a surrogate marker of vascular function, but it is still not clear whether 
it is a cause or effect of atherosclerosis [45].
Endocan or endothelial cell specific molecule-1 (ESM-1) is a novel endothelium-derived solu-
ble proteoglycan [46]. It binds to a wide range of bioactive molecules associated with cellular 
signaling and adhesion. It is involved in regulation of proliferation, differentiation, migration, 
and adhesion of different types of cells in health and disease. The endocan concentration is 
related to endothelial activation and neovascularization [47]. Endocan levels are elevated in 
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conditions such as tumor progression, hypertension, chronic kidney disease, and renal trans-
plant rejection [48]. Tadzic et al. [49] have described an increased expression of cell adhesion 
molecules, intracellular adhesion molecule’s (ICAM) and vascular cell adhesion molecule’s 
(VACM) ligands, together with decrease of sCAMs and endocan in hypertensive patients 
on amlodipine therapy with reduction in blood pressure, suggesting de-activation of endo-
thelium. Systolic and diastolic blood pressure was positively correlated with ICAM-1 and 
VCAM-1, and systolic blood pressure was negatively correlated with CD11a/LFA-1. Endocan 
significantly positively correlated with ICAM-1 [49].
Diabetes is associated with increased circulating levels of endothelium-derived adhesion 
molecules and plasminogen activator inhibitor-1, which have pro-inflammatory and pro-
thrombotic effects [50, 51]. In endothelial dysfunction, the endothelium can express adhesion 
molecules responsible for the withdrawal of leukocytes from vascular wall, such as VCAM-1 
and ICAM-1 [36]. Also, E-selectin and platelet endothelial cell adhesion molecule have been 
expressed in atherosclerotic lesions and are involved in mononuclear cell adhesion to the 
vascular endothelium [52, 53]. The main difference in the activation of adhesion molecules 
is that the expression of ICAM-1 increases after cell activation, while E-selectin and VCAM-1 
are only induced after cell activation. It is demonstrated that hyperglycemia results in the 
expression of adhesion molecules: endothelial-leukocyte adhesion molecule-1, VCAM-1, and 
ICAM-1 in human vascular endothelial cells [54]. In the rat mesenteric microcirculation, only 
intraperitoneal co-administration of IL-1β with D-glucose increased leukocyte rolling flux, 
Novel biomarkers System/cells Effect
Metabolic/biochemical
ADMA Inhibitor NOS Endothelial dysfunction
MMP2, MMP9
TIMP2, TIMP9
Intercellular matrix Intracellular matrix rearrangement
Myeloperoxidase (MPO) Activated neutrophils and 
macrophages
Production of oxidative stress
ox-LDL, 8-hydroxy-2′-deoxygunosine.
MDA (lipid peroxidation), protein 
carbonyl (PCO)
Lipids, activated proteins Reactive oxygen species and products 
(with increased oxidative stress
IL-6, TNF-alfa lymphocytes Proinflammatory cytokines
Toll-like receptor 4 lymphocytes Innate immunity
NO metabolites (nitrates, nitrites) Endothelium (NO) Vasodilation (NO) and nitrosylation
Functional/structural
Flow-mediated dilation (FMD) Blood vessels (endothelial 
function)
NO dependent, or COX, EDHF, EDCF 
dependent
Intima-media thickness (IMT) Blood vessels (endothelial 
function + VSMC)
multifactorial
Table 1. Potential novel biomarkers of atherosclerosis.
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adhesion, and migration, indicating that pro-inflammatory environment in diabetes is a criti-
cal factor in pro-atherosclerotic effects of hyperglycemia [54, 55].
Increased concentration of plasma glucose activates the endothelium [56–58]. Exposure of 
arterial tissue to increased glucose level induces superoxide production and impairs NO 
bioavailability in the vascular wall which leads to increased oxidative stress in these condi-
tions [59]. In diabetes mellitus, the production of superoxide and NADPH oxidase activity 
are increased [60, 61] which promote activation of the pro-inflammatory transcription factor 
NFκB [56]. The transcription factor NFκB is one of key regulator of endothelial activation 
and is included in insulin resistance [62, 63]. This is supported by study in obese persons 
[64]. Salsalate (an anti-inflammatory drug) increased expression of the inhibitor of NF-κB 
and reduced NFκB activation in freshly isolated endothelial cells taken from obese persons. 
Salsalate increased brachial artery flow-mediated dilation and reduced nitrotyrosine and 
expression of NADPH oxidase p47(phox) in these endothelial cells [64]. Table 1 presents 
some of the proposed novel biomarkers for atherosclerosis, which could also be related to 
other cardiometabolic diseases.
3. Functional biomarkers of vascular (endothelial) function
3.1. Assessment of microvascular endothelial function
3.1.1. Coronary microvascular function assessment
In the past, coronary angiography (of larger conductance arteries, i.e., coronary vessels) was 
considered a gold standard for evaluation of the severity and extent of CAD. However, in the 
last two decades, the attention was shifted to the coronary microcirculation as the possible 
site of anatomical and functional abnormalities crucial for the development and progression 
of final myocardial ischemia. Thus, functional assessment of coronary microcirculation and 
its endothelial function became a challenge. For a long time, measurement of changes in coro-
nary blood flow (CBF) during coronary angiography (Doppler wires) has been used as a sur-
rogate parameter for coronary microvascular function assessment [65]. The final result of this 
measurement is assessment of coronary flow reserve (CFR) which presents the ratio between 
the maximal CBF during maximal coronary hyperemia (provoked by adenosine infusion, 
pacing, or exercise) and the resting CBF. It has been demonstrated that CFR is both endothe-
lium-dependent and endothelium-independent, and CFR below 2.0 is considered abnormal 
[66]. For coronary microvascular endothelium-dependent vasodilation assessment, instead 
of maximal CBF, CBF in response to endothelium-dependent vasodilator (commonly ACh) 
infused at increasing concentrations is calculated. Another method for the assessment of coro-
nary microvascular function includes the measurement of the number of cineangiographic 
frames that it takes to fill a distal vessel with proximal injection of contrast. This method is 
named Thrombolysis in Myocardial Infarction (TIMI) and provides semi-quantitative assess-
ment of epicardial coronary blood flow [67]. The main advantage of the abovementioned 
methods is to measure microvascular endothelial function directly in this clinically important 
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vascular bed. However, main limitations are the cost, invasive nature, and therefore a limited 
population in which these measurements can be actually performed (symptomatic individu-
als requiring invasive coronary angiography) [68].
In recent years, a number of other methods have been developed among them: (a) blood 
oxygen level-dependent (BOLD) magnetic resonance imaging (MRI), a functional test that 
detects a dissociation of tissue hemoglobin from blood flow, is shown to be a useful tool 
for coronary endothelial function assessment [69]; (b) positron-emission tomography (PET) 
myocardial perfusion imaging that is based on the assessment of regional myocardial blood 
flow both at rest and during various forms of vasomotor stress [70] and presents a powerful 
tool to evaluate the effects of CV risk factors on the health of the microvasculature and its 
endothelium [71]; and (c) myocardial perfusion echocardiography, a bedside method with 
relatively low cost that is capable to detect myocardial perfusion abnormalities and quantify 
regional and global coronary blood flow [72]. Despite the fact that these new methods manage 
to provide noninvasive evaluation of coronary microvasculature directly at the site, they are 
still unacceptable for routine screening due to their limited availability, expensive equipment 
and associated costs, and lack of experienced/trained staff. Considering that endothelial func-
tion is a systemic disorder, peripheral vascular beds and their microcirculation present a good 
alternative that provides an easier access and need less elaborate equipment.
3.1.2. Venous occlusion plethysmography
Venous occlusion plethysmography presents a semi-invasive technique (arterial puncture) for 
assessment of forearm blood flow (and the corresponding microcirculation) changes before 
and after infusion of vasoactive substances into a cannulated brachial artery [3]. The method 
was introduced 90 years ago by Hewlett and van Zwaluwenburg [73], and the basic meth-
odology has changed little since its first description. Basic principle of this method is to stop 
the return of venous blood from the forearm (inflating the cuff over the diastolic pressure 
value) with the preserved arterial blood inflow to the forearm, leading to a linear increase in 
blood flow at a given time, which is proportional to the arterial blood inflow. Another cuff 
excludes the blood flow through the hand to reduce the temperature fluctuations of the blood 
flow depending on the temperature. Changes in the flow are recorded by changing the elec-
trical resistance of the plethysmograph located around the longest part of the forearm [74]. 
The main advantage of this method is that it provides assessment of endothelium-dependent 
and -independent vasodilation and mechanisms mediating it by intra-arterial infusion of 
vasoactive substances (e.g., ACh or sodium nitroprusside, and SNP), hormones, and drugs. 
However, its important limitation is that it could not strictly discern between macro- and 
microcirculation. Final results are expressed as ratio between blood flow changes in both 
arms and are well reproducible [75]. Regarding the mechanisms, some studies reported that 
ACh-induced dilation was inhibited by a NOS inhibitor, L-NG-monomethyl Arginine citrate 
(L-NMMA) [76], suggesting that NO is the main vasodilator mediating endothelium-depen-
dent vasodilation in this vascular bed. On the other hand, others reported that EDHF has 
a crucial role in mediating microvascular endothelial-dependent vasodilation, especially in 
population with multiple CV risk factors [77]. A large number of studies used venous occlu-
sion plethysmography to assess the association between endothelial dysfunction and CV risk 
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 factors, and described it in hypercholesterolemia [78], diabetes mellitus [79], cigarette smok-
ing [80], and aging [81], while the results in hypertensive patients were conflicting [3, 4, 82, 83]. 
Even though the method and pharmacologically induced vasodilation provide an insight into 
peripheral microvascular patho(physiology), venous occlusion plethysmography is charac-
terized by several limitations and disadvantages, including its semi-invasive character, lim-
ited comparison between groups due to different initial blood pressure and forearm blood 
flow, different sizes of the forearm, etc., [68].
3.1.3. Reactive hyperemia peripheral arterial tonometry (RH-PAT)
RH-PAT is a noninvasive technique designed for assessment of peripheral microvascular func-
tion. This method reflects changes in finger pulse volume amplitude during reactive hyper-
emia (an equivalent to finger plethysmography). PAT device includes digital probes that are 
placed on the tip of each index finger and a blood pressure cuff (for provoking occlusion) 
that is placed around the upper arm of the study arm, while the other arm serves as a control 
[84, 85]. Vascular occlusion is provoked by inflation of the blood pressure cuff to a 50 mmHg 
above systolic blood pressure for 5 min. The PAT signal is recorded 10 min prior occlusion, 
and for 10 min after the cuff is deflated. The final result of this measurement is calculated as 
the ratio of average amplitude of the PAT signal over a period of 1 min, starting 1 min after 
cuff deflation to average amplitude of the PAT signal for 3 min at baseline (RH-PAT index) 
that is normalized to the control arm [84, 85]. Studies have shown that RH-PAT is at least 
partly NO dependent. Importantly, studies by Rubinshtein et al. and Akiyama et al. reported 
that RH-PAT may be a useful tool for prediction of future CV events in patients with CV risk 
[86, 87]. Advantages of this method are that it is noninvasive, it is very simple and reproduc-
ible, and that it is operator independent (RH-PAT index is measured automatically). Even 
though RH-PAT is very similar to FMD of the brachial artery, Framingham Heart Study has 
revealed that there was no significant correlation between RH-PAT and FMD [88]. Moreover, 
the same study reported that different CV risk factors contribute differently to changes in 
FMD and RH-PAT [89], suggesting that these two methods assess different vascular beds, and 
that macro- and microvascular endothelium is differently susceptible to various risk factors.
3.1.4. Laser Doppler (LD) flowmetry
Because of its easy accessibility, the skin presents an appropriate site to study peripheral 
microcirculation, which was proposed as a suitable marker of systemic microvascular func-
tion in various diseases [89]. Therefore, in recent years, a number of simple and noninva-
sive methods have been developed in order to assess peripheral microcirculation. Still, it is 
an open question whether skin microcirculation is actually a representative indicator of the 
microvascular function of other organs. Despite that skin microvascular function was exten-
sively used over the past 30 years to investigate vascular mechanisms in various diseases 
including hypertension [90, 91], obesity [92], diabetes [93, 94], aging, kidney disease [95], etc.
The laser Doppler (LD) technique is based on the estimation of the flow rate in the skin 
microcirculation using the laser beam reflection from the erythrocyte in microcirculation 
and its wavelength change (Doppler’s effect) [96]. Computer software determines the flow 
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size, which is rather an index of skin perfusion (flux) than direct measure of skin blood flow. 
Results are commonly expressed in arbitrary units (perfusion units, PU) or as cutaneous vas-
cular conductance (CVC; flux divided by arterial pressure in mV/mmHg) [96]. The first devel-
oped technique was the laser Doppler flowmetry (LDF) that measures blood flow in a single 
point and thus over a small volume but with a high sampling frequency. A major limitation 
of this technique is its spatial variability, due to regional heterogeneity of skin perfusion and 
blood flow measurement in a single point [97]. Later, laser Doppler imaging (LDI) was devel-
oped, which provides a 2D image of skin microvascular perfusion using the same principle 
as LDF. Since this method assess flow over larger surface than LDF, it managed to reduce 
spatial variability, but it appears to be much slower than LDF, making rapid changes in blood 
flow difficult to record [98]. Both techniques are commonly used for microvascular reactivity 
assessment in response to various stimuli, including iontophoresis of vasoactive drugs, post-
occlusive reactive hyperemia (PORH), and thermal challenges [98].
Microdialysis is a technique based on intradermal insertion of small fibers for continuous 
delivery of drugs into a small area of tissue. This type of drug delivery provides avoiding 
its systemic effect [99] and it provides controlled drug application and absence of current-
induced vasodilation, compared to iontophoresis. However, microdyalisis is invasive and 
painful, and justifies the use of local anesthesia which might also affect the blood flow and 
thus impact the results. It was commonly used to assess the role of NO in PORH and the ther-
mal hyperemia response of skin microcirculation measured with LDF [98].
Iontophoresis is a method for noninvasive transdermal drug delivery (charged molecules) 
using low-density electric current. ACh and SNP iontophoresis are widely used for assess-
ment of endothelium-dependent and endothelium-independent vasodilation of skin micro-
circulation [98, 100]. Regarding endothelium-dependent dilation, studies reported that 
ACh-induced dilation seems to be predominantly mediated by COX metabolites (although 
results are still conflicting) [101, 102], and NO does not extensively contribute to such dilation 
[103] in skin microcirculation. Beside endothelial-dependent vasodilation, ACh administra-
tion induces neural axon reflex-mediated dilation as well [104]. Iontophoresis is associated 
with several issues: (a) current itself may induce nonspecific vasodilation, which could inter-
fere with the vasodilation potency of administrated drug, and it was suggested that it depends 
on the delivered electrical charge and the current delivery pattern [105]; (b) current-induced 
dilation also may depend on vehicles that have been used to dilute drugs (e.g., tap water, dis-
tilled water, deionized water, and saline), but this was not observed for ACh and SNP [106]; 
(c) skin resistance may influence drug delivery, and thus reduce skin resistance which was 
suggested as a part of good practice [100]; (d) spatial variability of ACh and SNP, suggesting 
that monitoring larger areas using LDI, rather than LDF provides better reproducibility [107, 
108]; and (e) site of iontophoresis, since for example SNP-induced dilation could not be pro-
voked on finger pulp, but it was provoked on the dorsum of the finger [109]. To summarize, 
ACh and SNP iontophoresis is widely used for endothelium-dependent and -independent 
microvascular vasodilation assessment in both healthy and various diseases. However, when 
interpreting results, complexity of mechanisms involved in these responses should be taken 
into account. Moreover, studies using iontophoresis should be carefully designed to reduce 
non-specific current-induced dilation by using low intensity current; saline should be rather 
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used as vehicle than distilled water; pre-treatment with anesthetic should be considered; and, 
finally, skin resistance should be reduced as much as possible.
PORH refers to an increase in (micro)vascular blood flow due to transient short vascular occlu-
sion, and represents a test that is commonly used for assessment of microvascular reactivity 
[98]. According to the literature, several mechanisms are involved in microvascular PORH 
response, including sensory nerves involvement via neural axon reflex [110], metabolic and 
myogenic component, and endothelial-dependent vasodilators production. Regarding endo-
thelium, EDHF was suggested as an important mediator of PORH [9], while the role of prosta-
glandins is still not clarified [11, 12]. Studies have reported that eNOS inhibition does not alter 
PORH, suggesting that NO is not normally involved in forearm microvascular PORH [111]. 
It has been suggested that inhibition of COX inhibition may unmask the NO dependence of 
PORH in human cutaneous circulation [12]. Despite an evident role of endothelium-derived 
vasoactive mediators in skin microvascular PORH, it should be used as a tool for assess-
ment of general microvascular reactivity, rather than a measure for microvascular endothelial 
function [89]. PORH can be used in conjunction with both LDF and LDI, but an advantage 
is given to the LDF, because LDI is considered too slow to track microvascular kinetics dur-
ing PORH. Moreover, inter-day reproducibility of single-point LDF was excellent when the 
probe was placed on exactly the same site from one day to another [112]. While recording 
skin microvascular PORH homogenizing both skin and room temperature is important, since 
temperature plays a key role in regulation of baseline flux [97]. Another issue is related to the 
PORH measurement, and that is heterogeneity in study design, especially vascular occlusion 
duration (from 1 to 15 min) [113] and different cuff pressures used, ranging between 160 and 
220 mmHg [114]. Although it is accepted as a good tool for microvascular reactivity assess-
ment, this method still requires standardization.
Local thermal hyperemia (LTH) presents peripheral skin microvascular response to local 
heating mediated by joint effect of neural-dependent and NO-dependent vasodilator path-
way [98]. LTH is characterized by initial peak (within the first 5 min) which depends on sen-
sory nerves, and by sustained plateau which is mostly NO-dependent [115]. LTH has better 
reproducibility in conjunction with LDI, rather than a single-point LDF, and this reproduc-
ibility depends on the site of measurement too [97]. Similar to PORH, there is heterogeneity 
in the study design using LTH, including local warming temperature (42–43°C) [116], the 
time of heating, and the nature of the device used to heat the skin [89]. Another used thermal 
stimulus is local cooling that induces an initial vasoconstriction followed by transient vaso-
dilation, and finally, prolonged vasoconstriction [116]. It has been demonstrated that initial 
vasoconstriction depends on norepinephrine, and prolonged vasoconstriction involved both 
norepinephrine and inhibition of NO system [116]. Results have shown that this method has 
the best reproducibility when the cooling protocol lasts for 30 min at 15°C [97].
Laser speckle contrast imaging is a novel technique that combines advantages of LDF and LDI, 
with very good inter-day reproducibility for both PORH and LTH measurements [117, 118]. 
This method is based on speckle contrast analysis that provides an index of blood blow. A 
potential limitation of this technique is its sensitivity to movements and potential challenging 
data analysis, but despite limitations, this method is expected to be a remarkable tool for micro-
vascular function assessment, especially when coupled with PORH and/or LTH [89].
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3.1.5. Fingertip digital thermal monitoring (DTM)
Fingertip digital thermal monitoring (DMT) of vascular reactivity represents a noninvasive, 
reproducible, operator-independent technique based on changes in fingertip temperature 
during cuff-occlusive reactive hyperemia [119]. This method relies on a premise that changes 
in fingertip temperature during and after vascular occlusion that reflects changes in blood 
flow and thus microvascular and endothelial function [120]. So far, studies have reported that 
vascular function measured by DTM correlate with Framingham Risk Score and coronary 
artery calcium score (a measurement of the amount of calcium in the walls of the coronary 
arteries using a special computed tomography (CT) scan of heart) independently of age, sex, 
and traditional cardiac risk factors [121]. Although clinical implications of DTM are promis-
ing, more studies on the mechanisms mediating this vascular response and large prospective 
trials are needed to establish the real research and clinical value of this method.
3.2. Assessment of macrovascular function
3.2.1. Flow-mediated dilation
FMD of the brachial artery is the most widely used noninvasive in vivo method for an indi-
rect assessment of endothelial function of conduit vessels introduced by Celermajer and col-
leagues [5]. It provides decisive information about the ability of the endothelium to respond 
to particular stimulus (reactive hyperemia). In this method, an arterial occlusion cuff is placed 
to the forearm and inflated to stop the anterograde blood flow, thus generating ischemia. 
Consequently, distal from that the occlusion, in the resistance arteries, vasodilation occurs, 
and when the sphygmomanometer is deflated, reactive hyperemia occurs in the brachial 
artery. The method involves ultrasound arterial imaging in two conditions, at rest (baseline) 
and during reactive hyperemia after 5 min arterial occlusion, and FMD is expressed as the 
% difference between that two measured diameters [122]. The exact mechanism mediating 
FMD during reactive hyperemia has not been fully elucidated; it is considered that shear 
stress-induced NO is the main mediator [76, 85], but also other endothelium-derived vasodi-
lator factors may also contribute [123]. Because reactive hyperemia flow, induces increased 
shear stress on endothelium challenges FMD, it might be a significant measure of periph-
eral microvascular function because reactive hyperemia is greatly dependent on maximal 
forearm resistance [124]. Furthermore, peripheral endothelial function as assessed by FMD 
correlates with vascular function of coronary artery [125]. In addition, impaired FMD is one 
of the early manifestations of vascular disease, and may be an important indicator of endo-
thelium injury [126].
However, although the principle of this technique seems simple, its application is techni-
cally challenging and requires comprehensive practicing and standardization [127, 128]. Easy 
access of this noninvasive method is one of the main advantages of this method, while other 
advantages being a good correlation with invasive epicardial vascular function assessment, 
possibility to assess other important parameters (i.e., flow, baseline arterial diameters and 
flow-mediated constriction), and low costs [68].
To ensure that impaired FMD is not due to underlying vascular smooth muscle dysfunc-
tion or alterations in vascular structure but truly a consequence of endothelial dysfunction, 
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response to nitroglycerine is used [127, 129, 130]. Nitroglycerine-induced vasodilation was 
significantly reduced in patients with cardiovascular disease [129]. Additionally, nitro-
glycerine-induced vasodilation was impaired in patients with atherosclerosis [131]. FMD 
should be interpreted as an index of vascular function reflecting both endothelium-depen-
dent and -independent vasodilation in individuals with impaired nitroglycerine-induced 
vasodilation [129]. Furthermore, coronary artery dilation in response to nitroglycerine is 
impaired in patients with coronary heart disease which predicts long-term atheroscle-
rotic disease progression and cardiovascular event rate [132]. These findings suggest that 
nitroglycerine-induced vasodilation per se may be a marker of the grade of atherosclero-
sis and predictor of cardiovascular events. However, the relationship between nitroglyc-
erine-induced vasodilation and the risk for future cardiovascular events should still be 
established.
3.2.2. New method for assessment of endothelial function—measurement of ezFMD
Since FMD requires an expensive ultrasound system and high levels of technical skills, a 
novel method for measurement of endothelial function, namely, measurement of enclosed-
zone flow-mediated dilatation (ezFMD) was developed [133]. ezFMD is a noninvasive 
method which assesses the level of vasodilatation from the oscillation signals transmitted to 
a sphygmomanometer cuff attached to the upper arm. In patients with cardiovascular dis-
eases, ezFMD was significantly lower than in age- and gender-matched healthy individuals. 
In addition, cardiovascular risk factors were independent predictors of ezFMD. ezFMD was 
significantly correlated with conventional FMD [134]. Conventional measurement of FMD 
by ultrasound is measured by the change in vascular diameter, whereas ezFMD is based on 
the change in vascular volume. Both methods are equally valuable for assessing endothelial 
function, however, measurement of ezFMD is easier and less biased than measurement of 
FMD.
3.2.3. Coronary epicardial vasoreactivity
Quantitative coronary angiography (QCA) or intravascular ultrasound are methods for imag-
ing vasomotor responses of epicardial coronary arteries, which enable tracing of changes in 
vessel diameters in response to endothelium-dependent interventions, e.g., intracoronary 
infusion of drugs or substances, such as acetylcholine [2]. Vessels with an intact endothelium 
vasodilate in response to ACh infusion, whereas segments with dysfunctional endothelial 
cells display abnormal vascular response [2]. Estimation of coronary endothelial function 
with intracoronary ACh provides diagnostic and prognostic data in patients with suspected 
coronary microvascular dysfunction.
Some of advantages of this method is direct assessment of the coronary vascular bed and rep-
resents gold standard for assessment of epicardial macrovasculature, while its disadvantage 
is invasiveness and limitation to those patients undergoing coronary angiography [68].
Physiologically, endothelium-dependent vasodilation occurs in response to exercise or 
tachycardia as a replacement for exercise, but also pacing induced tachycardia, and leads 
to increased flow-mediated endothelium-dependent vasomotion of the epicardial vessels 
that is impaired in atherosclerosis [68]. In healthy isolated intramyocardial porcine  coronary 
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 resistance arteries, bradykinin, serotonin, and the alpha 2-adrenergic agonist clonidine 
evoked endothelium-dependent relaxations, which were fully (clonidine) or partially (sero-
tonin) mediated by NO, while vasodilator response to bradykinin seems to be mediated by 
some other endothelium-derived mediator, different from NO [135]. Further, cold pressor test 
(CPT), in which the subject puts his hand into ice water, is another mode to assess epicardial 
vasoreactivity. In the study by Nabel et al., the response to CPT was assessed in patients with 
angiographically normal coronary arteries, in patients with mild coronary atherosclerosis and 
in patients with advanced coronary stenosis, using quantitative angiography and Doppler 
flow velocity measurements. Normal vessels exhibited vasodilation (partly related to beta-
adrenergic receptor stimulation and partly due to flow-mediated dilation or alpha-2 adrener-
gic receptor activation) while atherosclerotic vessels exhibited vasoconstriction in response to 
CPT, possibly due to altered sensitivity to adrenergic stimulation and/or some other impair-
ment of endothelium-dependent vasodilation [136].
3.2.4. Pulse wave velocity
Pulse wave velocity (PWV) is the velocity at which the pulse pressure wave spreads from 
the left ventricle (at the end of ventricular ejection) to the periphery. It results in an earlier 
return of the reflected wave which increases the pressure and subsequently the afterload of 
the left ventricle and reduces coronary artery perfusion pressure during diastole. One of the 
most frequently used noninvasive methods for the assessment of aortic stiffness is carotid-
femoral (aortic) PWV [137]. It is a simple, noninvasive, and reproducible method which has 
been used as a gold standard and provides a predictive value of aortic stiffness for future 
cardiovascular events [138]. PWV has been used as significant marker of cardiovascular risk. 
Data indicate that increased arterial stiffness is being independently predictive of coronary 
artery disease, stroke, and cardiovascular events in general [139]. While PWV values are 
lower in healthy young individuals, the values of PWV increase with reduction of arterial 
elasticity [140].
Applanation tonometry is another method that is used for pulse wave analysis. Rather than 
directly assessing aortic pulse wave, it estimates aortic pulse wave from the common carotid 
artery or the radial artery pulse waves. As the measurement is easier, radial artery tonometry 
has been the most commonly recommended approach [137]. Since the method can detect 
changes that might be related to vascular health, even before the onset of signs and symptoms, 
yet, the PWV analysis occupies an important place in clinical practice [141]. This method has 
some limitations that are related to associated comorbidities, such as metabolic syndrome, 
obesity, and diabetes, because the femoral pressure waveform may be difficult to record accu-
rately in these patients [137].
3.2.5. Intima-media thickness
Carotid intima-media thickness (CIMT) is a method that evaluates extra-cranial carotid 
arteries by high-resolution ultrasound, and represents an important marker of subclini-
cal atherosclerosis [142]. CIMT is increased in atherosclerosis and also correlates with 
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coronary artery disease [143] and cerebrovascular disease [144]. CIMT represents the 
combined width of the intima and media; in healthy individuals, it is composed almost 
entirely of media, with a progressive intimal thickening or hypertrophy of media, deter-
mined by age, gender, and hypertension [145]. The major advantage of CIMT is that it is 
noninvasive and reproducible, relatively inexpensive to perform, also widely available 
and well standardized [146].
3.2.6. Functional endothelial biomarkers in cardiovascular diseases
The baseline pathogenic process in cardiovascular diseases, such as atherosclerosis and coro-
nary artery disease, is an endothelial dysfunction with complex underlying mechanisms: oxi-
dative stress, diminished vasoreactivity, hemostatic disturbances, and inflammation leading 
to the disease progression by modulating the arterial wall, promoting lipoprotein retention, 
plaque formation and possibly its destabilization. Endothelial dysfunction is characterized 
by endothelial dysfunction, impaired vascular homeostasis and reduced “anti”-mechanisms 
(-oxidant, -inflammatory, -thrombotic) and activated “pro”-mechanisms. Diagnostic tools for 
detecting endothelial dysfunction in humans are limited. They should be safe, cost-effective, 
noninvasive, repeatable, reproducible, and standardized. Current diagnostic methods are 
FMD, forearm plethysmography, finger-pulse plethysmography, PWV analysis, and coro-
nary angiography. However, there is a need for additional diagnostic tools, biomarkers. For 
everyday clinical use, more and larger human-based studies are necessary to validate clinical 
usefulness of biomarkers [147, 148].
4. Conclusion
To find a specific and sensitive biomarker for any disease sometimes looks like a search for 
the Holy Grail—something precious but impossible to find. The reason for that could be those 
cardiometabolic diseases, all having a common point—endothelial dysfunction and it is likely 
that they have common underlying mechanisms leading to endothelial dysfunction. These 
mechanisms may be redundant and not activated at the same time and the same order, but 
certainly end up with impaired endothelium, and inappropriate vascular response to physi-
ological stimuli with inability to compensate for pathophysiological events, finally leading 
to manifested disease and organ damage. One can only take with “a grain of salt” as many 
different biomarkers as possible and build up a picture of their relationship to the disease’s 
etiopathogenesis, development, and prognosis.
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